FDA Approves First Drug to Treat Tardive Dyskinesia

Lauren Santye, Assistant Editor
Published Online: Wednesday, April 12th, 2017
The FDA approved valbenazine (Ingrezza) for the treatment of tardive dyskinesia, a neurological disorder that results in involuntary movements.
Tardive dyskinesia is a serious adverse event (AE) of antipsychotic medications that can develop in some patients. It usually effects the jaw, lips, and tongue, and involves involuntary movements such as smacking of the lips, sticking out the tongue, and grimacing.
The approval was based on a clinical trial that examined the efficacy of valbenazine compared with placebo in 234 patients with tardive dyskinesia, according to a press release.
After 6 weeks, the study results showed that patients who received valbenazine saw improvement in the severity of abnormal involuntary movements compared with patients in the placebo arm.
“Tardive dyskinesia can be disabling and can further stigmatize patients with mental illness,” Mitchell Mathis, MD, director of the Division of Psychiatry Products in the FDA’s Center for Drug Evaluation and Research, said in the release. “Approving the first drug for the treatment of tardive dyskinesia is an important advance for patients suffering with this condition.”
Valbenazine may cause serious AEs, including sleepiness and heart rhythm problems (QT prolongation). Patients with congenital long QT syndrome or with abnormal heartbeats associated with a prolonged QT interval should avoid the use of valbenazine.
Patients taking valbenazine should not drive or operate heavy machinery or engage in other dangerous activities until it is known how the drug affects them, according to the release. 

Current Issue

The Educated Patient

Kristen Marjama, DNP, APRN-BC
Although the rate of foot and leg amputation has greatly declined over the past 2 decades, increasing awareness for macrovascular and microvascular complications of diabetes is essential because diabetes is the leading cause of lower-limb amputations in the United States.
Kristen Marjama, DNP, FNP-BC
Gluten proteins found in barley, rye, and wheat trigger systemic injury primarily to the small intestine, but they can also affect the joints, liver, skin, uterus, and other organs.
Kristen Marjama, DNP, FNP-BC
It is that time of year again, when health care providers see an increase in patient volume because no one has time to be sick.
Sara Marlow, MSN, RN, PHN, FNP-C
Sunburn is still a major health issue that can be prevented.
$vacMongoViewPlus$ $vAR$
Contemporary Clinic
MJH Associates
American Journal of Managed Care
MD Magazine
Pharmacy Times
Specialty Pharmacy Times
Targeted Oncology
About Us
Contact Us
Terms & Conditions
Pharmacy Healthcare & Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-257-0701

Copyright Contemporary Clinic 2018
Pharmacy Healthcare & Communications, LLC. All Rights Reserved.